These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22292566)

  • 1. Identification of new epilepsy treatments: issues in preclinical methodology.
    Galanopoulou AS; Buckmaster PS; Staley KJ; Moshé SL; Perucca E; Engel J; Löscher W; Noebels JL; Pitkänen A; Stables J; White HS; O'Brien TJ; Simonato M;
    Epilepsia; 2012 Mar; 53(3):571-82. PubMed ID: 22292566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge and promise of anti-epileptic therapy development in animal models.
    Simonato M; Brooks-Kayal AR; Engel J; Galanopoulou AS; Jensen FE; Moshé SL; O'Brien TJ; Pitkanen A; Wilcox KS; French JA
    Lancet Neurol; 2014 Sep; 13(9):949-60. PubMed ID: 25127174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
    Barker-Haliski M; Steve White H
    Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies.
    Löscher W
    Epilepsy Res; 2016 Oct; 126():157-84. PubMed ID: 27505294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP).
    Kehne JH; Klein BD; Raeissi S; Sharma S
    Neurochem Res; 2017 Jul; 42(7):1894-1903. PubMed ID: 28462454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.
    Löscher W; Schmidt D
    Epilepsia; 2011 Apr; 52(4):657-78. PubMed ID: 21426333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1873-1888. PubMed ID: 28290134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do we choose the appropriate animal model for antiseizure therapy development?
    Barker-Haliski M
    Expert Opin Drug Discov; 2019 Oct; 14(10):947-951. PubMed ID: 31248287
    [No Abstract]   [Full Text] [Related]  

  • 9. Epilepsy therapy development: technical and methodologic issues in studies with animal models.
    Galanopoulou AS; Kokaia M; Loeb JA; Nehlig A; Pitkänen A; Rogawski MA; Staley KJ; Whittemore VH; Dudek FE
    Epilepsia; 2013 Aug; 54 Suppl 4(0 4):13-23. PubMed ID: 23909850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.
    Simonato M; Löscher W; Cole AJ; Dudek FE; Engel J; Kaminski RM; Loeb JA; Scharfman H; Staley KJ; Velíšek L; Klitgaard H
    Epilepsia; 2012 Nov; 53(11):1860-7. PubMed ID: 22708847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues for new antiepilepsy drug development.
    Simonato M; French JA; Galanopoulou AS; O'Brien TJ
    Curr Opin Neurol; 2013 Apr; 26(2):195-200. PubMed ID: 23406913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments.
    Löscher W
    Neuropharmacology; 2020 May; 167():107605. PubMed ID: 30980836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new treatment approaches for epilepsy: unmet needs and opportunities.
    French JA; White HS; Klitgaard H; Holmes GL; Privitera MD; Cole AJ; Quay E; Wiebe S; Schmidt D; Porter RJ; Arzimanoglou A; Trinka E; Perucca E
    Epilepsia; 2013 Aug; 54 Suppl 4():3-12. PubMed ID: 23909849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation.
    Terrone G; Salamone A; Vezzani A
    Curr Pharm Des; 2017; 23(37):5569-5576. PubMed ID: 28950818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.
    Wilcox KS; West PJ; Metcalf CS
    Neuropharmacology; 2020 Apr; 166():107811. PubMed ID: 31790717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.
    Barker-Haliski ML; Johnson K; Billingsley P; Huff J; Handy LJ; Khaleel R; Lu Z; Mau MJ; Pruess TH; Rueda C; Saunders G; Underwood TK; Vanegas F; Smith MD; West PJ; Wilcox KS
    Neurochem Res; 2017 Jul; 42(7):1904-1918. PubMed ID: 28303498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.
    Brooks-Kayal AR; Bath KG; Berg AT; Galanopoulou AS; Holmes GL; Jensen FE; Kanner AM; O'Brien TJ; Whittemore VH; Winawer MR; Patel M; Scharfman HE
    Epilepsia; 2013 Aug; 54 Suppl 4(0 4):44-60. PubMed ID: 23909853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically targeting transient receptor potential channels for seizures and epilepsy: Emerging preclinical evidence of druggability.
    Jiang J; Yu Y
    Pharmacol Ther; 2023 Apr; 244():108384. PubMed ID: 36933703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
    Löscher W; Potschka H; Sisodiya SM; Vezzani A
    Pharmacol Rev; 2020 Jul; 72(3):606-638. PubMed ID: 32540959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New avenues for anti-epileptic drug discovery and development.
    Löscher W; Klitgaard H; Twyman RE; Schmidt D
    Nat Rev Drug Discov; 2013 Oct; 12(10):757-76. PubMed ID: 24052047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.